Two big rivals in diabetes, Sanofi and Novo Nordisk, are promoting new 2-in-1 combination treatments for patients who fail to control their condition with insulin or oral drugs. Novo Nordisk’s ...

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability to red ...

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy ... as Pfizer's weekly injection Hympavzi and Novo Nordisk's daily Alhemo.